CORCEPT THERAPEUTICS INC

Insider buying at Corcept Therapeutics signals confidence amid regulatory uncertainty, offering investors a bullish view on its cortisol‑modulating therapy pipeline and strong cash reserves.

Corcept Therapeutics insider trading reveals strategic liquidity moves, not loss of confidence—monitor sales, buying patterns, and governance shifts for investment insight.

Corcept Therapeutics insider buy: William Guyer snaps 20,000 shares at half market price, signaling confidence in cortisol‑modulating pipeline and potential upside.

Corcept Therapeutics insider buying signals confidence amid litigation; investors gain insight into market strategy, competitive positioning, and drug‑development prospects.

CEO sells 26,000 Corcept shares under a 10b‑5 plan after FDA Lifyorli approval, reflecting disciplined liquidity management rather than market speculation.

Corcept insider buying signals confidence in its GR‑II obesity therapy, as CEO William Guyer’s 2026 trades hint at future upside amid a competitive market and clinical progress.

Corcept Therapeutics insider trades reveal portfolio rebalancing, not distress, amid rising social‑media buzz—watch leadership moves for future growth signals.

James Wilson’s $0.00 sale of 28,000 Corcept shares shows insider tactical rebalancing amid a 15% month‑to‑date dip; investors should watch for future moves that could signal company milestones.

Insider buying by Corcept Therapeutics’ owner signals confidence despite FDA and legal headwinds, offering investors a stabilizing signal amid market volatility.

Corcept Therapeutics insiders buy 1.18 M options, boosting confidence amid a 41% share decline and pending fraud lawsuit.